Applications of nanotechnology in vaccine development for coronavirus (SARS-CoV-2) disease (Covid-19)

Ravindra B. Malabadi, Neelambika T. Meti and Raju K. Chalannavar
Additional contact information
Ravindra B. Malabadi: Department of Applied Botany, Mangalore University, Mangalagangotri-574199, Mangalore, Karnataka State, India
Neelambika T. Meti: Plant Biotechnology Laboratory, Rajiv Gandhi Institute of IT and Biotechnology, Bharati Vidyapeeth University, Pune-Satara Road, Katraj, Pune – 411046, Maharashtra State, India
Raju K. Chalannavar: Department of Applied Botany, Mangalore University, Mangalagangotri-574199, Mangalore, Karnataka State, India

International Journal of Research and Scientific Innovation, 2021, vol. 8, issue 2, 191-198

Abstract: This review paper highlights the use of nanotechnology as a new opportunities for the development of novel strategies in terms of prevention, detection, diagnosis and treatment of severe acute respiratory syndrome coronavirus (SARS-CoV-2). Coronavirus (SARS-CoV-2) disease (covid-19) infection is characterized by severe respiratory diseases, including bronchiolitis, pneumonia, high fever, throat infections, and common cold. SARS-CoV-2 infection is not limited to any particular class, and people of all age groups are vulnerable. The coronavirus is airborne mainly transmitted through droplets from the infected person or symptomatic patients or from asymptomatic people. The transmission of SARS-CoV-2 from one human to another human is much faster, which has already resulted in its spread around the world and led the WHO to declare the covid-19 outbreak as a global pandemic. These outbreaks have tested the limits of healthcare systems and have posed serious questions about anagement using conventional therapies and diagnostic tools. Therefore, new controlling measures to overcome this covid-19 pandemic is the development of a suitable and cost effective vaccines and therapeutics. Hence nanotechnology platforms in the development of vaccines and therapeutic drugs have been developed based on nanomedicine, and have the potential to become innovative alternatives for overcoming COVID-19. A nano-based (mRNA-lipid nanoparticle) formulation for SARS-CoV-2 vaccine and therapeutics is being developed as a delivery vehicle and found successful.

Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.rsisinternational.org/journals/ijrsi/d ... -issue-2/191-198.pdf (application/pdf)
https://www.rsisinternational.org/virtual-library/ ... -2-disease-covid-19/

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bjc:journl:v:8:y:2021:i:2:p:191-198

Access Statistics for this article

International Journal of Research and Scientific Innovation is currently edited by Dr. Renu Malsaria

More articles in International Journal of Research and Scientific Innovation from International Journal of Research and Scientific Innovation (IJRSI)
Bibliographic data for series maintained by Dr. Renu Malsaria ().